Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Rhea-AI Summary

Evelo Biosciences (Nasdaq: EVLO) has announced a conference call scheduled for October 29, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results and business updates. The call can be accessed via phone or a live webcast on Evelo's investor website. The company is focused on developing orally delivered biologics that target the small intestinal axis, with promising candidates aimed at treating inflammatory diseases and cancer. Their leading products include EDP1815, EDP1867, EDP2939, and EDP1503.

Positive

• Evelo is developing oral biologics targeting SINTAX, potentially offering effective treatment options.
• The company has multiple product candidates in development for treating inflammatory diseases and cancer.

Negative

• None.

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights.

To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 5480508. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact

Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com

FAQ

What date is Evelo Biosciences reporting its Q3 2020 financial results?

Evelo Biosciences will report its Q3 2020 financial results on October 29, 2020.

How can I access the conference call for Evelo Biosciences?

The conference call can be accessed by calling 866-795-3242 for domestic or 409-937-8909 for international callers, using conference ID 5480508.

What are the main product candidates of Evelo Biosciences?

Evelo's main product candidates include EDP1815, EDP1867, EDP2939, and EDP1503, targeting inflammatory diseases and cancer.

Where can I find the archived version of the conference call?

The archived version of the conference call will be available on Evelo's website approximately two hours after the event and for 30 days following.